It's worth remembering that they had US FDA approval on the Prizma for awhile now. Have also had CE approval in Europe on both the Prizma and the patch for awhile now also with no sales.
Hard to expect EUA on the patch is automatically going to lead to immediate sales.
Hoping the patch gets better feedback than the Prizma.
https://medicalfuturist.com/prizma-g2-medical-smartphone-case-review/
Agree that corona is unprecedented but lack of sales for products they have in markets they have had approvals for is still concerning especially given Europe was first to have a mass outbreak.
Still can't also understand why they would contract another party in Israel to build the devices when they have spent so much on getting a facility in Chian built and certified.
Not sure this is as much of a certainty as others on here and think the price reflects that.
Still hopeful and hold. Last purchase was at 3.9c as it just seemed stupidly cheap, but if we don't see sales in the next two months, there is a chance we may revisit this.
- Forums
- ASX - By Stock
- GMV
- GMV The Future
GMV The Future, page-1816
-
- There are more pages in this discussion • 1,198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online